ctDNA can detect minimal residual disease in curative treated non-small cell lung cancer patients using a tumor agnostic approach.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Rosenlund Lærke, Guldbrandsen Kasper, Ahlborn Lise Barlebo, Bloch Martin, Skougaard Kristin, Albrecht-Beste Elisabeth, Nellemann Hanne Marie, Krakauer Martin, Gørtz Peter Michael, Fledelius Joan, Nielsen Anne Lerberg, Holdgaard Paw Christian, Nielsen Søren Steen, Grüner Julie Marie, Højsgaard Anette, Petersen Rene Horsleben, Møller Lars Borgbjerg, Dahl Morten, Frank Malene Støchkel, Ehlers Jeanette Haar, Saghir Zaigham, Pøhl Mette, Borissova Svetlana, Land Lotte Holm, Kristiansen Charlotte, McCulloch Tine, Mortensen Lise Saksø, Christophersen Malene Søby, Hilberg Ole, Rasmussen Thor Lind, Simonsen Schwaner Signe Høyer, Laursen Christian B, Bodtger Uffe, Lonsdale Markus Nowak, Meyer Christian Niels, Gerke Oke, Mortensen Jann, Rasmussen Torben Riis, Hjorthaug Karin, Larsen Klaus Richter, Meldgaard Peter, Fischer Barbara Malene, Sorensen Boe Sandahl
Аннотация
METHODS: We analyzed samples from 45 NSCLC patients recruited in a prospective national multicenter study, all of whom had undergone curative treatment. A total of 38 pre-treatment plasma samples and 76 post-treatment plasma samples were examined using a commercially available cancer personalized profiling by deep sequencing (CAPP-seq) strategy, and a tumor-agnostic approach. Post-treatment samples were collected at two distinct landmark time points: Follow-up 1 (0.5-4.5 months post-treatment) and Follow-up 2 (4.5-7.5 months post-treatment).
RESULTS: Detectable ctDNA post-treatment was significantly associated with increased risk of tumor recurrence and shorter recurrence-free survival (RFS). Using only a single blood sample taken from Follow-up 2, we correctly identified MRD in 50% of the patients who later experienced recurrence. However, subgroup analysis further revealed that in patients treated with radiotherapy or chemoradiotherapy (CRT), ctDNA detection was significantly linked to shorter RFS in the MRD analysis from Follow-up 2, but not in the MRD analysis from Follow-up 1.
CONCLUSION: These findings suggest that post-treatment ctDNA, detected using a tumor-agnostic approach, is a reliable biomarker for predicting recurrence in NSCLC patients following curative treatment. However, the optimal timing for blood sampling to detect MRD appears to depend on the type of curative treatment received.